Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy
- 27 March 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 19 (6), 1308-1319
- https://doi.org/10.1158/1535-7163.mct-19-0791
Abstract
Cancer patients often confront the decision of whether to continue high dose chemotherapy at the expense of cumulative toxicities. Reducing the dose of chemotherapy regimens while preserving efficacy is sorely needed to preserve the performance status of these vulnerable patients, yet has not been prioritized. Here, we introduce a dual pronged approach to modulate the microenvironment of desmoplastic pancreatic tumors and enable significant dose de-escalation of the FDA-approved chemotherapeutic nanoliposomal irinotecan (nal-IRI) without compromising tumor control. We demonstrate that light-based photodynamic priming (PDP) coupled with vitamin D3 receptor (VDR) activation within fibroblasts increases intratumoral nal-IRI accumulation and suppresses pro-tumorigenic CXCL12/CXCR7 crosstalk. Combined photodynamic and biochemical modulation of the tumor microenvironment enables a 75% dose reduction of nal-IRI while maintaining treatment efficacy, resulting in improved tolerability. Modifying the disease landscape to increase the susceptibility of cancer, via preferentially modulating fibroblasts, represents a promising and relatively underexplored strategy to enable dose de-escalation. The approach presented here, using a combination of three clinically available therapies with non-overlapping toxicities, can be rapidly translated with minimal modification to treatment workflow, and challenges the notion that significant improvements in chemotherapy efficacy can only be achieved at the expense of increased toxicity.Other Versions
Funding Information
- NIH (P01CA084203, UH3CA189901, S10ODO1232601)
- NIH (K99CA194269, R00CA194269)
- NIH (R00CA175292)
This publication has 48 references indexed in Scilit:
- A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancerBritish Journal of Cancer, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cellsJournal of Translational Medicine, 2012
- Induction of Immune Mediators in Glioma and Prostate Cancer Cells by Non-Lethal Photodynamic TherapyPLOS ONE, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Stimulation of anti-tumor immunity by photodynamic therapyExpert Review of Clinical Immunology, 2011
- CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapyBritish Journal of Cancer, 2010
- CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progressionCancer and Metastasis Reviews, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009